Abexinostat

Drug Profile

Abexinostat

Alternative Names: CG-781; CRA-024781; PCI-24781; S 78454

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celera Genomics Group
  • Developer GlaxoSmithKline; Massachusetts General Hospital; Pharmacyclics; Servier; University of California at San Francisco
  • Class Amides; Antineoplastics; Benzofurans; Dimethylamines; Hydroxamic acids; Phenyl ethers; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
  • Phase I/II Sarcoma
  • No development reported Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Breast cancer; Myelodysplastic syndromes; Nasopharyngeal cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-lymphoblastic-leukaemia(Second-line therapy or greater) in France (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in France (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease) in France (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top